PROGNOSIS AND PROGNOSTIC FACTORS IN NODE-NEGATIVE CERVIX CANCER

Citation
M. Stockler et al., PROGNOSIS AND PROGNOSTIC FACTORS IN NODE-NEGATIVE CERVIX CANCER, International journal of gynecological cancer, 6(6), 1996, pp. 477-482
Citations number
21
Categorie Soggetti
Obsetric & Gynecology",Oncology
ISSN journal
1048891X
Volume
6
Issue
6
Year of publication
1996
Pages
477 - 482
Database
ISI
SICI code
1048-891X(1996)6:6<477:PAPFIN>2.0.ZU;2-F
Abstract
Relapse rates, mortality rates and possible prognostic factors were as sessed in women with early-stage, node-negative cervix cancer. We iden tified 194 women who had a radical hysterectomy with histopathological ly confirmed negative lymph nodes as primary treatment for FIGO stages IB and IIA cervix cancer between 1981 and 1990, at a single tertiary referral oncology centre. Each patient's pathology was reviewed by two pathologists blinded to patient outcome. Clinical and demographic det ails were abstracted from medical records by a single observer blinded to patient outcome. Median follow-up was 5.3 years and 95% were follo wed for longer than 2 years. Prognostic significance for relapse-free survival was assessed with Cox's proportional hazards model. There wer e 27 relapses (relapse-free survival probability of 85% (95% confidenc e interval (CI): 79-90)) and 19 deaths (overall survival probability 8 6% (95%CI: 78-93)), of which 17 were due to cervix cancer (cervix canc er specific survival probability 87% (95%CI: 80-94)). Nuclear grade 2 or 3 (P = 0.02) and small-cell squamous histology (P = 0.01) were each associated with about a four-fold increase in the risk of recurrence, while lymphatic permeation (P = 0.02), age less than 36 years (P = 0. 03) and either tumor size >28 mm (P = 0.03) or surgical clearance <5 m m (P = 0.02) were each associated with about a 2.5-fold increase in th e risk of recurrence. Adverse histologic features, young age and large tumor size were independent predictors of increased recurrence rates in these women with early-stage cervix cancer.